Brief: FDA Grants Breakthrough Therapy Designation To Seres Therapeutics’ SER-155

Seres Therapeutics

09/12/2024 12:13

Dec 9 (Reuters) - Seres Therapeutics Inc  MCRB.O :
    * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO SERES
THERAPEUTICS’ SER-155 FOR REDUCTION OF BLOODSTREAM INFECTIONS IN
ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
(ALLO-HSCT)
    * SERES THERAPEUTICS INC - FDA MEETING ON NEXT STUDY OF
SER-155
EXPECTED IN Q1 2025

Source text:  ID:nGNX4hrFb6 
Further company coverage:  MCRB.O 

 ((Reuters.Briefs@thomsonreuters.com;))